Serologic responses in patients with malignant mesothelioma. Evidence for both public and private specificities

American Journal of Respiratory Cell and Molecular Biology

Volumn 22, Issue 5, 2000, Pages 550-556

  Robinson, Cleo ^a   Callow, Marinella ^a   Stevenson, Sandra ^a   Scott, Bernadette ^a   Robinson, Bruce W S ^a   Lake, Richard A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; CDNA LIBRARY; CELL NUCLEUS; COMPLEMENTARY DNA; IMMUNE RESPONSE; IMMUNOGLOBULIN G; MALIGNANT MESOTHELIOMA; MOLECULAR CLONING; SERODIAGNOSIS; SURVIVAL; TUMOR DIAGNOSIS; WESTERN BLOTTING;

ANIMALIA;

EID: 0034079702     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.22.5.3930     Document Type: Article

References (44)

1. 1. Ruffie, P. 1992. Pleural mesothelioma. Curr. Opin. Oncol. 4:334-341.
2. 2. Robinson, B. W. S. 1993. Development of new therapeutic strategies for mesothelioma. Lung Cancer 9:413-418.
3. 3. Christmas, T. I., L. S. Manning, M. J. Garlepp, A. W. Musk, and B. W. Robinson. 1993. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:9-12.
4. 4. Robinson, B., R. Bowman, L. Manning. A. Musk, and G. van Hazel. 1993. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. Eur. Respir. Rev. 3:220-222.
5. 5. Upham, J., A. Musk, G. van Hazel, M. Byrne, and B. Robinson. 1993. Interferon alpha and doxorubicin in malignant mesothelioma. Aust. N. Z. J. Med. 23:683-687.
6. 6. Davis, M. R., L. S. Manning, D. Whitaker. M. J. Garlepp, and B. W. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52:881-886.
7. 7. Bielefeldt, O. H., D. R. Fitzpatrick, A. L. Marzo, A. G. Jarnicki, R. P. Himbeck, M. R. Davis, L. S. Manning, and B. W. Robinson. 1994. Patho-and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol. Immunother. 39:347-359.
8. 8. Leong, C. C., B. W. Robinson, and M. J. Garlepp. 1994. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int. J. Cancer 59:212-216.
9. 9. Bielefeldt, O. H., A. L. Marzo, R. P. Himbeck, A. G. Jarnicki, B. W. Robinson, and D. R. Fitzpatrick. 1995. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 40:241-250.
10. 10. Garlepp, M. J., and C. C. Leong. 1995. Biological and immunological aspects of malignant mesothelioma. Eur. Respir. J. 8:643-650.
11. 11. Robinson, C., B. W. S. Robinson, and R. A. Lake. 1998. Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 20:175-184.
12. 12. Tureci, O., U. Sahin, and M. Pfreundschuh. 1997. Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today 3:342-349.
13. 13. Boon, T., J. C. Cerottini, B. Vandeneynde, P. Vanderbruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. 12:337-365.
14. 14. Pardoll, D. M. 1994. Tumour antigens: a new look for the 1990s. Nature 369:357-358.
15. 15. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
16. 16. Brichard, V., P. A. Van, T. Wolfel, C. Wolfel, P. E. De, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
17. 17. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin. and J. P. Szikora. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
18. 18. Haraguchi, M., S. Yamashiro, A. Yamamoto, K. Furukawa, K. Takamiya, K. O. Lloyd, H. Shiku, and K. Furukawa. 1994. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2, 8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:10455-10459.
19. 19. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515-3519.
20. 20. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
21. 21. Salgaller, M. L., J. S. Weber, S. Koenig, J. R. Yannelli, and S. A. Rosenberg. 1994. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39:105-116.
22. 22. Marzo, A. L., R. A. Lake, D. Lo, L. Sherman, A. McWilliam, D. Nelson, B. W. S. Robinson, and B. Scott. 1999. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 162:5838-5845.
23. 23. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59:1071-1079.
24. 24. Manning, L. S., D. Whitaker, A. R. Murch, M. J. Garlepp. M. R. Davis, A. W. Musk, and B. W. Robinson. 1991. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer 47:285-290.
25. 25. Palmer, J. P., C. M. Asplin, P. Clemons, K. Lyen, O. Tatpati, P. K. Raghu, and T. L. Paquette. 1983. Insulin antibodies in insulin dependent diabetics before insulin treatment. Science 222: 1337-1339.
26. 26. Lubin, R., G. Zalcman, L. Bouchet, J. Tredaniel, Y. Legros, D. Cazals, A. Hirsch, and T. Soussi. 1995. Serum p53 antibodies as early markers of lung cancer. Nature Medicine 1:701-702.
27. 27. Noguchi, Y., Y. T. Chen, and L. J. Old. 1994. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91: 3171-3175.
28. 28. Schlichtholz, B., Y. Legros, D. Gillet, C. Gaillard, M. Marty, D. Lane, F. Calvo, and T. Soussi. 1992. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:6380-6384.
29. 29. Zamore, P. D., J. G. Palton, and M. R. Green. 1992. Cloning and domain structure of the mammalian splicing factor U2AF. Nature 355:609-614.
30. 30. Imai, H., E. K. Chan, K. Kiyosawa, X. D. Fu, and E. M. Tan. 1993. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J. Clin. Invest. 92:2419-2426.
31. 31. Walker, C., F. Rutten, X. Yuan, H. Pass, D. M. Mew, and J. Everitt. 1994. Wilm's tumor suppressor gene expression in rat and human mesothelioma. Cancer Res. 54:3101-3106.
32. 32. Davies, R. C., C. Calvio, E. Bratt, S. H. Larsson, A. I. Lamond, and N. D. Hastie. 1998. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev. 12:3217-3225.
33. 33. Maheswaran, S., C. Englert, P. Bennett, G. Heinrich, and D. A. Haber. 1995. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9:2143-2156.
34. 34. Matsuzawa, S., S. Takayama, B. A. Froesch, J. M. Zapata, and J. C. Reed. 1998. p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. EMBO J. 17:2736-2747.
35. 35. Austin, C. A., and K. L. Marsh. 1998. Eukaryotic DNA topoisomerase II beta. Bioessays 20:215-226.
36. 36. Yuwen, H., C. C. Hsia, Y. Nakashima, A. Evangelista, and E. Tabor. 1997. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 234:194-197.
37. 37. Zhang, D., A. J. Paley, and G. Childs. 1998. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J. Biol. Chem. 273:18086-18091.
38. 38. Berglund, J. A., N. Abovich, and M. Rosbash. 1998. A cooperative interaction between U2AF65 and mBBP/SF1 facilitates branchpoint region recognition. Genes Dev. 12:858-867.
39. 39. Wrehlke, C., H. P. Schmitt-Wrede, Z. Qiao, and F. Wunderlich. I997. Enhanced expression in spleen macrophages of the mouse homolog to the human putative tumor suppressor gene ZFM1. DNA Cell Biol. 16:761-767.
40. 40. Amson, R. B., M. Nemani, J. P. Roperch, D. Israeli, L. Bougueleret, I. Le Gall, M. Medhioub, G. Linares-Cruz, F. Lethrosne, P. Pasturaud, L. Piouffre, S. Prieur, L. Susini, V. Alvaro, P. Millasseau, C. Guidicelli, H. Bui, C. Massart, L. Cazes, F. Dufour, H. Bruzzoni-Giovanelli, H. Owadi, C. Hennion, G. Charpak, and A. Telerman. 1996. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc. Natl. Acad. Sci. USA 93:3953-3957.
41. 41. Wang, X. Z., H. P. Harding, Y. Zhang, E. M. Jolicoeur, M. Kuroda, and D. Ron. 1998. Cloning of mammalian Ire1 reveals diversity in the ER stress responses. EMBO J. 17:5708-5717.
42. 42. Prieve, M. G., K. L. Guttridge, J. Munguia, and M. L. Waterman. 1998. Differential importin-alpha recognition and nuclear transport by nuclear localization signals within the high-mobility-group DNA binding domains of lymphoid enhancer factor 1 and T-cell factor 1. Mol. Cell Biol. 18:4819-4832.
43. 43. Chang, K., and I. Pastan. 1994. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (Ovcar-3) cell line. Int. J. Cancer 57:90-97.
44. 44. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92:11810-11813.